No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 674 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian... April 21, 2026 Experts Think Medical Detection Dogs Could Be Trained To Sniff Out... March 27, 2020 ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December November 26, 2021 Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL November 10, 2021 Load more HOT NEWS New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side... How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? Heine H. Hansen Award: Johan Vansteenkiste and Fiona Blackhall Honoured for... Can Eating Soy Cause Breast Cancer?
